Atara Biotherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | — |
| Research and development | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M |
| Operating expenses | — | — | — | $344.1M | $360.8M |
| Operating income | $35.9M | -$83.4M | -$276.0M | -$280.5M | -$340.5M |
| Interest expense | $3.8M | $4.6M | $5.3M | $373,000 | — |
| Pretax income | $32.7M | -$85.4M | -$276.1M | -$228.3M | -$340.1M |
| Income tax expense | $31,000 | -$12,000 | $15,000 | $12,000 | $46,000 |
| Net income | $32.7M | -$85.4M | -$276.1M | -$228.3M | -$340.1M |
| Balance Sheet | |||||
| Cash and equivalents | $8.5M | $25.0M | $25.8M | $92.9M | $106.1M |
| Current assets | $12.2M | $64.9M | $101.9M | $295.1M | $384.6M |
| Total assets | $20.2M | $109.1M | $165.5M | $376.4M | $468.1M |
| Current liabilities | $14.9M | $134.6M | $142.2M | $78.9M | $105.8M |
| Total liabilities | $58.7M | $206.4M | $264.7M | $249.8M | $188.5M |
| Stockholders' equity | -$38.5M | -$97.3M | $99.2M | $126.6M | $279.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$50.9M | -$68.7M | -$193.0M | -$270.4M | -$220.5M |
| Depreciation and amortization | $400,000 | $2.7M | $3.7M | $4.7M | $9.3M |
| Stock-based compensation | $9.8M | $27.0M | $45.4M | $53.8M | $53.9M |
| Capital expenditure | $0 | $246,000 | $1.2M | $4.2M | $10.6M |
| Free cash flow | -$50.9M | -$69.0M | -$194.2M | -$274.6M | -$231.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 9.0M
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.